Ozempic (semaglutide) and Victoza (liraglutide) are prescription drugs used to treat type 2 diabetes and reduce the risk of cardiovascular problems. Both drugs come as an injection. Ozempic is not ...

LOS ANGELES (KABC) -- Many people taking a popular diabetes medication have been experiencing weight loss as one of the side effects. Low blood sugar levels brought 59-year-old Anda Lam to her ...

CHICAGO (WLS) -- Geraldine Glass said her diabetes medication has been on back order for weeks because so many people are using the drug to lose weight. Drugs to treat diabetes have become ...

Unable to scale up its manufacturing fast enough to meet the spiraling demand for its GLP-1 weight loss products, Novo Nordisk is employing a new strategy—reducing production of diabetes drug Victoza ...

Victoza (liraglutide) is a prescription drug used to treat type 2 diabetes and lower the risk of cardiovascular problems in certain people. Mild side effects of the drug include nausea, diarrhea, and ...

Novo Nordisk launched a consumer campaign for Victoza, emphasizing the product’s ability to bring down blood sugar levels and body weight in patients with type 2 diabetes. The campaign features print ...

Branded content furnished by our promotional partners. The Daily Sundial editorial staff is not involved in its production. Content does not reflect the views or opinions of the editorial staff.

Victoza (liraglutide) and Ozempic (semaglutide) are two injectable drugs known as GLP-1 agonists used to treat people with type 2 diabetes. While some GLP-1 agonists are used for weight loss in people ...

Novo Nordisk's (NVO) new type-2 diabetes drug Victoza is rapidly gaining market share in the all-important U.S. market. The Danish drug maker's early commercial success with its subcutaneous "GLP-1" ...

Indication(s): As adjunct to diet and exercise, to improve glycemic control in type 2 diabetes. The approval of Victoza in this patient population was based on data from the ELLIPSE trial which ...

With one drugmaker already trying to pry patent protection off of Novo Nordisk’s blockbuster Victoza before its 2022 expiration, the insulin specialist has taken new steps to deter copies. The Danish ...

Two products for the treatment of type 2 diabetes, insulin degludec (Tresiba) and liraglutide (Victoza), both from Danish drug firm Novo Nordisk, have this week been given positive opinions for ...